AstraZeneca Expands Emphasis On China, Already A Key Market

 
• By Joseph Haas

UK pharma will invest $2.5bn in Beijing R&D hub, build a vaccine manufacturing site with BioKangtai, and partner in chronic disease with Syneron and in oncology/immunology with Harbour BioMed.

China map
AstraZeneca increases its efforts in China with $2.5bn commitment in Beijing (Shutterstock)

More from Deals

More from Focus On Asia